Leadership Team | Owl Therapeutics

The Owl Leadership Team

Our proven, cohesive leadership team is comprised of innovative and dedicated drug developers, scientists, clinicians, and business leaders.

Co-Founder & CEO

William Haskins

Dr. Haskins brings 20+ years experience in therapeutic R&D, including leadership roles at Genentech and Catalent. Well-versed in CNS biomarkers and large molecule drug development (OCREVUS®, KADCYLA®, POLIVY®, etc.).

Co-Founder & CTO

Franklin Okumu

Dr. Okumu brings 20+ years in R&D experience from Genentech, Novo Nordisk, and Dr. Reddy's (KADCYLA®, PERJETA®, DIFICID®, SERNIVO®, ZEMBRACESYMTOUCH®, IMPOYZ®, etc.)

Co-Founder & Chair of Scientific Advisory Board

Kevin K.W. Wang

Dr. Wang is renowned for work in TBI biomarkers. A pivotal figure in neurotrauma research and a leader in TBI commercialization. Expert Rev Mol Diagn 24, 67-77 (2024). https://doi.org:10.1080/14737159.2024.2306876

Co-Founder & Technical Advisor

Henry Lowman, PhD

Dr. Lowman brings 20+ years of leadership roles in antibody engineering at Genentech, NGM Biopharmaceuticals, CytomX Therapeutics, Triphase Accelerator U.S.

Co-Founder & Clinical Advisor

Todd Kilbaugh

Dr. Kilbaugh is the Associate Anesthesiologist in Chief and Associate Chair of Research for the Department of Anesthesiology and Critical Care Medicine at the Children’s Hospital of Philadelphia.